drugset
drugset / Trial / NCT04552808

To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects

NCT04552808 ↗

Phase 1 Completed 16 enrolled Sunshine Lake Pharma Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

To evaluate the pharmacokinetics and safety of Yimitasvir phosphate capsules in subjects with moderate and severe liver function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

Timeline

Start
2020-10-19
Primary completion
2022-06-09
Completion
2022-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Yimitasvir Small molecule 100 mg —

Indications

No indication recorded.